Seaport Therapeutics Inc SPTX

$18.05 -0.27 (-1.47%)

Valuation

Market cap
966,234,000
Revenue TTM
$0
Net income TTM
$-74,880,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
284,200
Avg volume
293,918
Day's range
$17.41 – $18.83
Shares out
53,531,000
Stochastic %K
13%
Beta
—
Analysts
Strong Buy
Price target
$37.43

Price

Company profile

Seaport Therapeutics, Inc., a clinical-stage therapeutics company, focuses on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. It is leveraging its proprietary Glyph platform to advance a pipeline of therapies to address the unmet needs in depression and anxiety. The company's lead product candidate, GlyphAllo (SPT-300 or Glyph Allopregna...

Show more

Seaport Therapeutics, Inc., a clinical-stage therapeutics company, focuses on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. It is leveraging its proprietary Glyph platform to advance a pipeline of therapies to address the unmet needs in depression and anxiety. The company's lead product candidate, GlyphAllo (SPT-300 or Glyph Allopregnanolone), is a novel, Glyphed oral prodrug of allopregnanolone, an endogenous molecule that has been clinically validated in third-party trials for the treatment of postpartum depression. Its second product candidate, GlyphAgo (SPT-320 or Glyph Agomelatine), is a novel, Glyphed oral prodrug of agomelatine, a clinically validated anxiolytic and antidepressant that is approved for the treatment of generalized anxiety disorder in Australia and major depressive disorder in Australia and the European Union. The company was founded in 2024 and is based in Boston, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
(617) 807-4062
Website
https://www.seaporttx.com
Address
101 Seaport Blvd., Floor 12, Boston, United States

Latest news

Stocktwits

d_risk Nov 5, 5:13 AM
$SPTX - Seaport Therapeutics, Inc. - 10Q - Updated Risk Factors Seaport disclosed that GlyphAgo is being evaluated in a Phase 2a proof-of-pharmacology trial and that it expects to initiate a Phase 2/3 trial in the first half of 2027. It also expects to complete first-in-human-enabling studies for Glyph2BLSD by year-end 2027. #Biopharmaceuticals #ClinicalTrials #CashBurn #RegulatoryRisks #EuropeanUnion 🟢 Added 🟠 Removed https://d-risk.ai/SPTX/10-Q/2026-11-02
0 replies
Quantumup Nov 3, 11:43 AM
Stifel reiterated $SPTX Buy-$30 following the Co's 3Q26 update, where everything remains on track. [SAGE AXSM JNJ Gate Neuro ITCI CMPS [PFE LLY HLUBF HLBBF VNDA BNOX MNMD]] Stifel said in its note: https://x.com/Quantumup1/status/2117583072996589790?a=kEDZFnZbkpUb2VMv7bs&s=20
0 replies
shoc24 Nov 2, 3:35 PM
$SPTX reported before the open this morning. GAAP EPS of −$0.49 beat the −$0.5685 analyst estimate by 13.8%, according to Stock Meadow.
0 replies
Quantumup Oct 21, 12:41 PM
Stifel reiterated $LBRX Buy-$53 and said -- We're reiterating our Buy rating on LBRX, after spending time with CEO Heather Turner, COO/CBO Gad Soffer, and CFO Joseph Miller at an investor lunch/NDR. $SNY $SPTX MPLT BMY PRAX JNJ ABBV RAPP OTSKY TEVA HLUBF HLBBF DRUG NBIX Here's what Stifel went on to say: https://x.com/Quantumup1/status/2112886895323566337?s=20
0 replies
NastyPelosi Oct 14, 6:19 PM
$QQQ $SPY my 3 best trades today on this drop are $SPTX $CYTK $CHEF I will still be in the red in total though but these 3 really held me up. 🙏
0 replies
Quantumup Oct 12, 7:38 PM
Guggenheim reit'd Best Idea $LBRX Buy-$80 ~ests LB-102 US peak sales in SCZ alone of $2.1B & $1.3B in bipolar depression, w/ adjunctive MDD not currently included in model SNY $SPTX MPLT BMY PRAX JNJ $ABBV RAPP OTSKY VNDA TEVA NMRA HLUBF HLBBF DRUG NBIX Here's what Guggenheim said in its note to investors: https://x.com/Quantumup1/status/2109730153660350732?s=20
0 replies
Quantumup Oct 8, 12:05 PM
H.C. Wainwright reiterated $SPTX Buy-$50 after Seaport announced that the first patient has been dosed in a Ph2a trial in Australia evaluating GlyphAgo, in adults w/ generalized anxiety disorder (GAD) and sleep disturbance. $DFTX $HELP LLY ABBV Here's what H.C. Wainwright said in its note: https://x.com/Quantumup1/status/2108166678848643165?s=20
0 replies
STACKD0E Oct 7, 5:17 PM 1 replies